Literature DB >> 30205890

Development of and Progression of Overt Heart Failure in Nonobstructive Hypertrophic Cardiomyopathy.

Yasmine L Hiemstra1, Philippe Debonnaire2, Erik W van Zwet3, Marianne Bootsma1, Martin J Schalij1, Jeroen J Bax1, Victoria Delgado1, Nina Ajmone Marsan4.   

Abstract

Only few studies aimed at identifying predictors of heart failure (HF) in hypertrophic cardiomyopathy (HC) patients. Furthermore, serial echocardiographic analyses are lacking in these patients and little is known about the natural progression of left ventricular (LV) abnormalities and their association with HF development. Aim of this study was to assess the prognostic value of LV global longitudinal strain (GLS) and other clinical and echocardiographic characteristics for the development of HF in patients with nonobstructive HC; furthermore, changes in echocardiographic parameters over time were correlated with HF development. Echocardiography was performed in 236 HC patients (68% men, age: 50 ± 14 years) at their initial visit and during follow-up (6.5(4.1 to 9.8) years). The end point of new HF development or progression to New York Heart Association class III/IV was noted and echocardiographic changes over time were compared among patients with and without HF using linear mixed model analysis. In total, 40 patients reached the HF end point. Multivariable cox regression analysis showed that age (HR 1.04(1.01 to 1.06), p = 0.016), New York Heart Association class (HR 2.30(1.07 to 4.95), p = 0.033), GLS (HR 1.15(1.05 to 1.22), p = 0.001), and left atrial volume (LAVI, HR 2.22(1.10 to 4.50), p = 0.027) were independently associated with the HF end point. Echocardiographic parameters, including GLS and LAVI, remained stable over time in patients without HF end point, but changed significantly in patients who developed HF (group-time interaction, p = 0.042 for GLS and p = 0.027 for LAVI). In conclusion, LV dysfunction is a progressive phenomenon in nonobstructive HC patients which can be detected by repeated echocardiography. Importantly, GLS and LAVI at baseline as well as their changes over time are associated with HF.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 30205890     DOI: 10.1016/j.amjcard.2018.04.038

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  3 in total

Review 1.  Hypertrophic Cardiomyopathy: Genetic Testing and Risk Stratification.

Authors:  Fergus Stafford; Kate Thomson; Alexandra Butters; Jodie Ingles
Journal:  Curr Cardiol Rep       Date:  2021-01-12       Impact factor: 2.931

2.  Clinical Relevance of the LVEDD and LVESD Trajectories in HF Patients With LVEF < 35.

Authors:  Yu-Chen Chen; Shi-Chue Hsing; Yuan-Ping Chao; Yung-Wen Cheng; Chin-Sheng Lin; Chin Lin; Wen-Hui Fang
Journal:  Front Med (Lausanne)       Date:  2022-05-13

3.  Model Embraced Electromechanical Coupling Time for Estimation of Heart Failure in Patients With Hypertrophic Cardiomyopathy.

Authors:  Su Hu; Lan Mi; Jianli Fu; Wangxia Ma; Jingsong Ni; Zhenxia Zhang; Botao Li; Gongchang Guan; Junkui Wang; Na Zhao
Journal:  Front Cardiovasc Med       Date:  2022-06-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.